Meningococcal C conjugate vaccine: The experience in England and Wales

被引：128
|
作者：
Campbell, Helen [1 ]
Borrow, Ray [2 ]
Salisbury, David [3 ]
Miller, Elizabeth [1 ]
机构：
[1] Hlth Protect Agcy Ctr Infect, Immunisat Hepatitis & Blood Safety Dept, London NW9 5EQ, England
[2] Manchester Royal Infirm, Hlth Protect Agcy NW, Meningococcal Reference Unit, Manchester M13 9WL, Lancs, England
[3] Dept Hlth, London SE1 6TE, England
来源：
VACCINE | 2009年 / 27卷
关键词：
Meningococcal serogroup C disease; Meningococcal C conjugate vaccine; Surveillance; INFLUENZAE TYPE-B; IMMUNOLOGICAL MEMORY; NEISSERIA-MENINGITIDIS; UNITED-KINGDOM; CHANGING EPIDEMIOLOGY; IMMUNIZATION CAMPAIGN; MASS IMMUNIZATION; VIRULENT CLONE; NO EVIDENCE; UK INFANTS;
D O I：
10.1016/j.vaccine.2009.04.067
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Meningococcal C conjugate vaccine was introduced in the UK in November 1999 together with a comprehensive meningococcal surveillance strategy to support and inform the vaccine programme. These surveillance data have provided important information on the long-term effectiveness of the programme, through direct and indirect protection, and on the prevalent serotypes and serosubtypes causing invasive meningococcal infection subsequent to vaccine introduction. The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：B20 / B29
页数：10
相关论文
共 50 条
  • [1] Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales
    Trotter, Caroline L.
    Edmunds, W. John
    Ramsay, Mary E.
    Miller, Elizabeth
    [J]. HUMAN VACCINES, 2006, 2 (02): : 68 - 73
  • [2] Effectiveness of meningococcal C conjugate vaccine in teenagers in England
    Bose, A
    Coen, P
    Tully, J
    Viner, R
    Booy, R
    [J]. LANCET, 2003, 361 (9358): : 675 - 676
  • [3] Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
    Ramsay, ME
    Andrews, N
    Kaczmarski, EB
    Miller, E
    [J]. LANCET, 2001, 357 (9251): : 195 - 196
  • [4] Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England
    Allan R. Tunkel
    [J]. Current Infectious Disease Reports, 2001, 3 (4) : 350 - 351
  • [5] Modelling cost effectiveness of meningococcal serogroup C conjugate vaccination campaign in England and Wales
    Trotter, CL
    Edmunds, WJ
    [J]. BRITISH MEDICAL JOURNAL, 2002, 324 (7341): : 809 - 812B
  • [6] Meningococcal serogroup C conjugate vaccine
    Lakshman, R
    Finn, A
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (01) : 87 - 96
  • [7] Impact of meningococcal C conjugate vaccine in the UK
    Balmer, P
    Borrow, R
    Miller, E
    [J]. JOURNAL OF MEDICAL MICROBIOLOGY, 2002, 51 (09) : 717 - 722
  • [8] No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales
    Trotter, Caroline L.
    Ramsay, Mary E.
    Gray, Stephen
    Fox, Andrew
    Kaczmarski, Edward
    [J]. LANCET INFECTIOUS DISEASES, 2006, 6 (10): : 616 - 617
  • [9] Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine
    Richmond, P
    Kaczmarski, E
    Borrow, R
    Findlow, J
    Clark, S
    McCann, R
    Hill, J
    Barker, M
    Miller, E
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (02): : 761 - 764
  • [10] IMMUNOGENICITY OF MENINGOCOCCAL-A AND MENINGOCOCCAL-C CONJUGATE VACCINE IN ADULTS
    BOWERS, T
    ANDERSON, E
    BELSHE, RB
    KENNEDY, D
    SIROTA, N
    MINK, CM
    [J]. CLINICAL RESEARCH, 1993, 41 (03): : A650 - A650
12345